CellVax Therapeutics, a privately-held clinical-stage company, was founded with the mission to innovate in the field of cancer immunotherapy. The company's core vision is to develop personalized, autologous cancer vaccines that harness the body's immune system to fight cancer. Their lead product, FK-PC101, targets prostate cancer patients at high risk of recurrence post-prostatectomy. Utilizing proprietary technology, FK-PC101 creates Tumor Presenting Cells (TPC) from the patient's own cancer cells to induce a multi-neoantigen immune response against cancer cells.
Notable figures associated with CellVax Therapeutics include Fernando Kreutz. The company has made significant strides in the development of FK-PC101, showcasing promising results in clinical trials. By focusing on personalized immunotherapy, CellVax Therapeutics aims to make a substantial impact on the treatment and management of cancer, potentially improving outcomes for patients with recurrent prostate cancer.
